UV Flu Technologies Announces Addition of Renowned Vice President of Sales
News Jun 05, 2011
UV Flu Technologies, Inc. has announced it has hired Denny Mulloy to assume the role of Executive Vice President of Sales, Marketing and Alliances for UV Flu, and its wholly owned subsidiary, Rx Air.
Mr. Mulloy has a long and distinguished career in various senior Sales and Marketing positions, with over 40 years experience with Fortune 100 companies such as NCR, Xerox, Dun and Bradstreet and I2 Technologies.
During the course of his career, he was named the number one salesperson at both Xerox and Dun and Bradstreet Software. He has been serving as Chief Operating Partner for Blue Green Partners, a green technology and services company located in Dallas, Texas.
"We are thrilled to have someone of Denny's caliber join us," said Jack Lennon, President of UV Flu. "Over the last 6 months, we have purchased RX Air, paid off almost all our debt, added numerous distributors, domestically and internationally, refocused our entire marketing approach, while also rebranding our marketing materials. Denny's addition will enable us to efficiently address our newly created demand and growth opportunities. His focus on the Sales, Marketing and Alliances function will enable us to compress our timeline for the pending international distribution agreements, as well as additional domestic distributors. This strategic decision will accelerate our new product development, and enhancement plans."
"Seldom have I encountered an opportunity as ripe for growth as I see with UV Flu and RX Air," said Denny Mulloy, new Executive Vice President of Sales for UV Flu and RX Air.
Mulloy continued, "This entire space is poised for growth, with much larger growth potential than what one would have seen 30 years ago before bottled water became popular. There is nothing more important to human health than the quality of the air we breathe 24 hours per day, but there is almost no attention or education being devoted to the sector. We are going to change this."
"The global impact to personal well being, and escalating health care costs are directly attributable to the significant rise in asthma, allergies, respiratory issues, and drug-resistant viruses. We're excited about the opportunity to enable people to live longer, healthier, and more productive lives, through the use of our proven, cost effective solutions. We're also confident of our ability to capture a healthy percentage, of what we think will become a $10 billion a year market over the next 5 years," said Mr. Mulloy.